Replies to post #245525 on Biotech Values

[sks144]

Those are all fair points. Do you think the P3 in TNBC will fail? I wonder why they structured it this way

[sks144]

Thinking through this more- aren’t most CRC tumors CDK 4/6 dependent, vs SCLC and TNBC? Why did they think this wouldn’t be a major risk to efficacy? Because they thought they could offset the toxicity of the 5FU and allow for greater exposure?

Makes me slightly more optimistic on TNBC